Abbreviations: CMML = chronic myelomonocytic leukemia; CR = complete remission; CRi = CR with incomplete count recovery; MRD = match related donor, MURD = match unrelated donor; NHL = non-Hodgkin lymphoma.
Non-myeloablative (NMA) and reduced intensity conditioning (RIC) allow older patients, those with comorbidities, and heavily pre-treated patients to undergo allogeneic hematopoietic cell transplantation (HCT). [1] [2] [3] Consequently, the use of NMA and RIC regimens has significantly increased in the past two decades. However, as relapse remains a significant limitation, conditioning regimens that minimize non-relapse mortality (NRM) associated with myeloablative conditioning (MAC) while protecting against relapse are needed.
We have previously reported the results in double unit cord blood transplantation (CBT) recipients of a novel RIC regimen using cyclophosphamide 50 mg/kg, fludarabine 150 mg/m 2 and thiotepa 10 mg/kg with 400 cGy TBI (Cy50/Flu150/Thio10/ TBI400). 4, 5 Based on favorable outcomes in CBT recipients, we investigated this regimen in recipients of PBSC transplants. Twenty consecutive patients transplanted at Memorial Sloan Kettering Cancer Center between 2008 and 2013 who received Cy50/Flu150/Thio10/TBI400 were included in this retrospective analysis after obtaining approval from the center's institutional review and privacy board. Patients with a hematological malignancy who were 18 years of age or greater with an HLA-matched or single-allele-mismatched related or unrelated donor were included. This regimen, along with GvHD prophylaxis and utilization of anti-thymocyte globulin (ATG), was selected for patients at the discretion of the treating provider if the patient was deemed to have high-risk disease for which MAC was not feasible either because of comorbidity or based on prior treatment. HLA matching was established by DNA sequence-specific oligonucleotide typing for HLA-A, -B, -C, -DRB1 and -DQB1 loci. Conditioning consisted of cyclophosphamide 50 mg/kg (day 6), fludarabine 30 mg/m 2 /day for 5 days (−6 to − 2), thiotepa 5 mg/kg/day for 2 (days -5 and -4) and TBI 200 cGy per day for 2 (days -2 and -1) with chemotherapy doses calculated on adjusted body weight in recipients over 125% of ideal body weight. GvHD prophylaxis consisted of tacrolimus and methotrexate (n = 5), sirolimus and tacrolimus with methotrexate (n = 12) or without methotrexate (n = 3). A recipient of a 9/10 HLA-matched unrelated donor (MUD) also received ATG. All patients received conventional PBSC grafts; nine each from HLA-matched related or MUDs and two from HLA-unrelated 1 allele mismatched donors (MMUD). Granulocyte CSF (5 μg/kg/day) was given from day 7 until neutrophil recovery. GvHD was diagnosed clinically, confirmed pathologically by biopsy whenever possible and classified according to standard criteria. 6, 7 The hematopoietic stem cell transplant-comorbidity index score (HCT-CI) 8 was assigned retrospectively. Data were updated as of June 2015. Overall (OS) and PFS were defined as the time from HCT until death from any cause and disease relapse or death, respectively. NRM was defined as death in a patient without disease relapse. Univariate probabilities and 95% confidence intervals of OS and PFS were estimated using Kaplan-Meier methodology, and survival distributions were compared across patient and treatment characteristics using the log-rank test. The cumulative incidence (CI) of NRM, disease relapse and GvHD was estimated based on the CI method of competing risks. Disease relapse, death in the absence of disease relapse and relapse or death in the absence of GvHD were considered competing risks for NRM, disease relapse and GvHD, respectively. All analyses were performed using R version 3.0.3 (R Foundation of Statistical Computing, Vienna, Austria).
Twenty patients (median age 52 years, range 27-70) underwent transplantation with Cy50/Flu150/Thio10/TBI400 ( Thirty-five percent of patients (n = 7) had a HCT-CI of 0, 15% of 1 (n = 3), 15% of 2 (n = 3) and 35% ⩾ 3 (n = 7). Comorbidities included: prior solid tumor (n = 1), pulmonary disease (n = 7), infection requiring antibiotics at the time of transplantation (n = 1), hepatic dysfunction (n = 7), cardiovascular disease (n = 1), arrhythmia (n = 1) and obesity (n = 1) with eight patients having more than one comorbid condition. Three patients had received prior transplants (one received an autologous stem cell transplant (ASCT) 2 years before HCT, one received an ASCT 14 years and an HCT 11 years before second HCT, and one had an HCT 5 years before second HCT). Of the patients with a HCT-CI of 0, one received both an ASCT and HCT, three were 460 and three received 43 lines of prior therapy. All patients achieved neutrophil engraftment with a median time to neutrophil recovery of 12 days (range 9-19 days). Eighteen patients had platelet recovery, one with delayed platelet recovery (median 12.5 days, range 8-70). CI of acute grade II GvHD (aGvHD) at 100 days was 30% (95% CI 12-51); no patients experienced grade III-IV aGvHD. Patients with aGvHD received grafts from unrelated donors (matched n = 6 and mismatch n = 1). CI of chronic GvHD (cGVHD) was 40% (95% CI 18-61) at 2 years ( Figure 1 ). Nine patients developed cGVHD, 5 from MRD (including with severe cGVHD), four from MUD (matched n = 3, mismatched n = 1). NRM was 15% (95% CI 4-34) and 25% (95% CI 9-46) at 1 and 2 years, respectively. Five patients died of transplant-related causes, three from GvHD (acute in two, chronic in one) and two from toxicity (one from liver failure and one from diffuse alveolar hemorrhage); no patient died of infection as the primary cause of death. Four patients (two with non-Hodgkin lymphoma (NHL), two with ALL of whom one also had MDS) relapsed for a CI of 20% (95% CI 6-40) at 2 years. Three of these patients died, and one patient with angioimmunoblastic T-cell lymphoma who was a recipient of a prior transplant and had received three lines of therapy is alive at last follow-up. As of June 2015, the median follow-up among surviving patients is 41 months (range, 26-82). OS at 1 and 2 years is 75% (95% CI 50-89) and 60% (95% CI 36-78), respectively. PFS at 1 and 2 years is 70% (95% CI 45-85) and 55% (95% CI 31-74), respectively ( Figure 2 ). When analyzing outcomes by HCT-CI, 1 and 2-year OS were decreased in patients with an HCT-CI ⩾ 1 (62% (95% CI 31-82) and 39% (95% CI 14-63), respectively), compared with patients with an HCT-CI of 0 (100% OS at both time points, P = 0.013)). Similarly 1 and 2-year PFS were decreased in patients with an HCT-CI ⩾ 1 (54% (95% CI 25-76) and 39% (95% CI 14-63), respectively), compared with patients with an HCT-CI of 0 (100 and 86% (95% CI 33-98), P = 0.045).
In this study we confirm that Cy50/Flu150/Thio10/TBI400 is a promising alternative, radiation-based conditioning regimen of intermediate intensity for patients with a variety of high-risk hematological malignancies undergoing HCT and ineligible for MAC. Patients with leukemia in this study were either heavily pre-treated or had significant comorbidities precluding the use of MAC. The remaining patients had histologies for which RIC would be considered standard. Although NMA regimens allow older patients and those with greater comorbidities to undergo HCT, relapse rates limit the success of this strategy. Only one study has shown similar outcomes in patients with AML in CR1 receiving RIC vs MAC regimens, although it should be noted that the conditioning in the RIC arm was relatively intense. 10 Successful incorporation of radiation to RIC regimens has the potential to decrease relapse rates by increasing conditioning intensity without the toxicities seen in MAC regimens. In the MAC setting, studies have shown comparable outcomes with TBI and non-TBI containing regimens. For NHL patients specifically, higher intensity regimens and those with radiation, lead to improved outcomes. However, the benefit in disease control is often offset by increased treatment related mortality (TRM), 11 especially after ASCT. 12 Herein we present a novel RIC regimen, which intensifies the conditioning over the Cy/Flu/TBI 200 cGy NMA 13 by adding 10 mg/kg of thiotepa and increasing the TBI up to 400 cGy with acceptable PFS and OS compared with other RIC regimens. 14, 15 The Cy50/Flu150/ Thio10/TBI400 regimen permits donor engraftment without significant treatment related toxicity. Rates of engraftment were high and no patient died secondary to infectious complications. In this study, only one patient received ATG; however, rates of GvHD were comparable to other studies using conventional grafts, although the regimens for GvHD were variable, limiting any conclusions regarding the optimal GvHD regimen for this conditioning strategy. Although this study is small, it suggests that ATG can be safely omitted when this regimen is utilized. NRM was 25.0% at 2 years, which is comparable to other studies using RIC.
14 Five patients had TRM, all of whom had comorbid conditions before treatment (HCT-CI of 1-6), and one patient had received a previous autologous and allogeneic transplant. In our study, HCT-CI predicted OS and PFS, despite the number of patients in the study being small. In addition, only one patient with an HCT-CI o 3 had a toxicity related death. Limitations of this study include its small size and heterogeneous patient population. However, our data suggest that this reduced intensity regimen incorporating 400 cGy is safe to administer in patients with highrisk disease not eligible for ablative HCT due to age or Letter to the Editor comorbidities. Prospective studies are required to validate this conditioning strategy for high-risk patients undergoing HCT.
